UnknownNot applicableNCT00287950
Combination Chemotherapy, Surgery, and Radiation Therapy in Treating Infants With Neuroblastoma
Studying Neuroblastoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Children's Cancer and Leukaemia Group
- Principal Investigator
- Penelope Brock, MD, PhD, M.D., Ph.DUniversity College London Hospitals
- Intervention
- carboplatin(drug)
- Enrollment
- 120 enrolled
- Eligibility
- 1 years · All sexes
- Timeline
- 1992
Study locations (22)
- Our Lady's Hospital for Sick Children, Dublin, Ireland
- Birmingham Children's Hospital, Birmingham, England, United Kingdom
- Institute of Child Health at University of Bristol, Bristol, England, United Kingdom
- Addenbrooke's Hospital at Cambridge University Hospitals NHS Foundation Trust, Cambridge, England, United Kingdom
- Leeds Cancer Centre at St. James's University Hospital, Leeds, England, United Kingdom
- Leicester Royal Infirmary, Leicester, England, United Kingdom
- Royal Liverpool Children's Hospital, Alder Hey, Liverpool, England, United Kingdom
- Royal London Hospital, London, England, United Kingdom
- Great Ormond Street Hospital for Children NHS Trust, London, England, United Kingdom
- Meyerstein Institute of Oncology at University College of London Hospitals, London, England, United Kingdom
- Central Manchester and Manchester Children's University Hospitals NHS Trust, Manchester, England, United Kingdom
- Sir James Spence Institute of Child Health, Newcastle upon Tyne, England, United Kingdom
- Queen's Medical Centre, Nottingham, England, United Kingdom
- Oxford Radcliffe Hospital, Oxford, England, United Kingdom
- Children's Hospital - Sheffield, Sheffield, England, United Kingdom
- +7 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00287950 on ClinicalTrials.govOther trials for Neuroblastoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2, PHASE3NCT07549321A Safety and Efficacy Study of hu14 in High-Risk Neuroblastoma PatientsRenaissance Pharma Ltd.
- RECRUITINGPHASE1, PHASE2NCT06625190Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid TumorsUniversity of Florida
- RECRUITINGPHASE1NCT07172958Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)Children's National Research Institute
- RECRUITINGPHASE2NCT07085338A Phase II Study With a Safety Run-In of the Addition of N-803 to a Chemoimmunotherapy Backbone for the Treatment of Patients With Relapsed or Refractory NeuroblastomaSt. Jude Children's Research Hospital
- RECRUITINGPHASE1, PHASE2NCT07399821An Imaging Study of Anti-GD2-800CW in Patients With NeuroblastomaPrincess Maxima Center for Pediatric Oncology
- RECRUITINGPHASE1NCT06995872Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory NeuroblastomaNational Cancer Institute (NCI)
- RECRUITINGPHASE1, PHASE2NCT06814496Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing TumorsUniversity of Arizona
- RECRUITINGPHASE1NCT07087002GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young AdultsStanford University